We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
3.50 | 0.23% | 1,529.50 | 1,531.50 | 1,532.00 | 1,541.50 | 1,523.00 | 1,537.00 | 8,077,646 | 16:35:26 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 12.79 | 63.05B |
Date | Subject | Author | Discuss |
---|---|---|---|
24/9/2019 09:02 | For a woman to have smashed the glass ceiling she isn't the best man for the job. She is clearly much better than that. | pcok | |
24/9/2019 08:55 | I would be embarrassed getting hired for a top job just to fill a diversity quota. Whatever happened to hiring the best man for the job? Ok best "person" whatever! | purplepelmets | |
23/9/2019 13:35 | Thanks Sogoesit | alotto | |
23/9/2019 12:48 | At last quarter I make the quick ratio about 0.70. Over 50% are trade payables. I would check your stock screener. | sogoesit | |
22/9/2019 16:08 | It probably means GSK has 5 pounds (assets) but they owe 10 pounds (debts) | abdullla | |
22/9/2019 06:49 | https://www.dailymai | ayl30 | |
20/9/2019 10:20 | They'll have been absorbed long before then. spud | spud | |
20/9/2019 10:14 | I think the cure for cancer will come from technology and not from medicine,the patient will be put on a sophisticated scanner which at a press of a button will recognise and kill all the cancerous cells in ones body,good and body friendly cells will be unaffected by this process,pharma industry will convert or collapse :0) | abdullla | |
20/9/2019 09:44 | Further alignment of healthcare and tech. Makes sense | ayl30 | |
20/9/2019 09:04 | And in her spare time ……. Four years ago Microsoft had just two women on its board. Emma Walmsley is now the fifth. | tradermichael | |
19/9/2019 12:20 | Henry took with him the medicine to live for ever its called the Wellcome trust and maybe a place in the heaven,now I let you decide to believe it or not ;) | abdullla | |
19/9/2019 11:56 | Henry Wellcome would be turning in his grave again ;0( | tradermichael | |
19/9/2019 11:26 | That would be one hundred billion pounds sterling and good bye to another jewel in the half empty crown:-) | abdullla | |
19/9/2019 10:57 | This company more likely to be taken out by one of the US giants if it continues to languish at these levels for too long, easy meat with the sterling rate so low! | wormhasturned | |
19/9/2019 10:33 | Agree key area here. | tim 3 | |
19/9/2019 10:26 | There's a battle between support and resistance at 1647p ….. ;0) | tradermichael | |
19/9/2019 10:03 | It seems the order book is full of sell orders | abdullla | |
18/9/2019 15:26 | Should be some news about the Pfizer Healthcare merger soon? | tradermichael | |
17/9/2019 16:19 | To go sub 15 GSK will have to issue a profit warning. | abdullla | |
17/9/2019 15:49 | Back here when sub 15. For years it has wanderef this range. Steady div though. More patience. And need more dip. Good company. | xxxxxy | |
17/9/2019 09:43 | Ad Com Wednesday for Glaxo OTC oral nicotine spray The FDA's Nonprescription Drugs Advisory Committee will meet on Wednesday, September 18, to review and discuss GlaxoSmithKline's (GSK -0.6%) marketing application for nicotine oral spray (1 mg per spray) as a smoking cessation aid in adults who are trying to stop smoking. | crossing_the_rubicon | |
13/9/2019 13:29 | Group PLC on Friday said as US judge has granted Vectura's motion for supplemental damages of around USD10.5 million in its case against GSK | abdullla |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions